| ［1］ James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 2005,434(7037)：1144-1148.
［2］ Tefferi A，Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms：the 2008 World Health Organization criteria and point-of-care diagnostic algorithms．Leukemia, 2008, 22(1):14-22．
［3］ 顾树程, 常春康. JAK2 V617F在骨髓增殖性肿瘤中的研究进展.现代中西医结合杂志， 2010, 19(6):769-771.
［4］ 袁利亚, 李红, 陈国安, 等. JAK2 V617F基因突变在骨髓增生性疾病中的发生率及其临床意义. 浙江大学学报(医学版), 2010, 39(2):202-206.
［5］ Pardanani A, Hood J , Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia, 2007, 21(8): 1658-1668.
［6］ Zeuner A, Pedini F, Francescangeli F, et al. Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. Blood, 2009, 113(7):1522-1525． |
